Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Expert Answers to Questions on PARP Inhibition for Prostate Cancer

In this podcast episode, listen to Charles J. Ryan, MD, and Neal D. Shore, MD, FACS, as they answer questions from a healthcare professional audience on the use of PARP inhibitors and PARP inhibitor combinations for patients with prostate cancer.
Charles J. Ryan, MD
Neal D. Shore, MD, FACS
Released: April 6, 2021

In this episode, Charles J. Ryan, MD; and Neal D. Shore, MD, FACS; answer questions from a healthcare professional audience on topics related to prostate cancer and PARP inhibition including:

  • Germline and somatic mutation testing
  • Managing adverse events with PARP inhibitors
  • Resistance to PARP inhibitors
  • Implications of monoallelic vs biallelic BRCA mutations
  • ATM mutations and PARP inhibitor sensitivity

Presenters:

Charles J. Ryan, MD
Professor of Medicine
B.J. Kennedy Chair in Clinical Medical Oncology
Director, Division of Hematology, Oncology and Transplantation
Department of Medicine
University of Minnesota
Oncologist
Division of Hematology, Oncology and Transplantation
University of Minnesota Health Clinics and Surgery Center
Minneapolis, Minnesota

Neal D. Shore, MD, FACS
Director
Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AstraZeneca
Merck Sharp & Dohme Corp.
Pfizer

Related Content

Podcast on ongoing and planned clinical trials using PARP inhibitors in combination with other therapies in patients with prostate cancer from Clinical Care Options (CCO)

Karim Fizazi, MD, PhD Joaquin Mateo, MD, PhD Released: April 19, 2021

In this slideset from Clinical Care Options (CCO), experts provide insights on clinical trials of PARP inhibitor combinations in prostate cancer

Karim Fizazi, MD, PhD Joaquin Mateo, MD, PhD Released: April 19, 2021

In this slideset from Clinical Care Options (CCO), experts present the rationale for PARP inhibitor combination therapies in prostate cancer

Karim Fizazi, MD, PhD Joaquin Mateo, MD, PhD Released: April 16, 2021

Podcast on the rationale for using PARP inhibitors in combination with other therapies in patients with prostate cancer from Clinical Care Options (CCO)

Karim Fizazi, MD, PhD Joaquin Mateo, MD, PhD Released: April 15, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue